Close
- Computational Platforms
- Repurposing of a drug: key considerations (UCL log-in required)
- REMEDi4ALL Repurposing Concierge
Computational Platforms
The specific pathway for repurposing a drug will be dependent on the availability of prior pharmaceutical and biological knowledge and requirement for understanding the drug’s mechanism of action.
Computational platforms can provide large amounts of known information to support the hypothesis generation in drug repurposing. An overview of some computational platforms & databases and their role in the repositioning pathway is shown below:
Database | Information |
A free search engine accessing primarily the MEDLINE database of references and abstracts on life sciences and biomedical topics | |
A database of chemical molecules and their activities against biological assays | |
Database that brings together excerpted pre-clinical, clinical and post-release safety data in a single longitudinal database and offers regulatory context with 2.2 million searchable pages of FDA approval packages. | |
A manually curated chemical database of bioactive molecules with drug-like properties | |
A database that identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) | |
Searchable database which provides information about current ongoing clinical research studies | |
A repository of data from GSK-Sponsored Clinical Studies, supplementing communication in journals, scientific meetings, and approved prescribing information | |
Access to patient level data from the GSK’s clinical trials | |
A centralized compilation of summary level findings from genetic association studies, both large and small. | |
Information on marketed medicines and their recorded adverse drug reactions |